Cargando…

Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?

COVID-19 may appear with a widely heterogeneous clinical expression. Thus, predictive markers of the outcome/progression are of paramount relevance. The neutrophil/lymphocyte ratio (NLR) has been suggested as a good predictive marker of disease severity and mortality. Accordingly, we found that NLR...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelzo, Monica, Cacciapuoti, Sara, Pinchera, Biagio, De Rosa, Annunziata, Cernera, Gustavo, Scialò, Filippo, Mormile, Mauro, Fabbrocini, Gabriella, Parrella, Roberto, Gentile, Ivan, Castaldo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239130/
https://www.ncbi.nlm.nih.gov/pubmed/34211953
http://dx.doi.org/10.3389/fpubh.2021.664108
_version_ 1783715012217405440
author Gelzo, Monica
Cacciapuoti, Sara
Pinchera, Biagio
De Rosa, Annunziata
Cernera, Gustavo
Scialò, Filippo
Mormile, Mauro
Fabbrocini, Gabriella
Parrella, Roberto
Gentile, Ivan
Castaldo, Giuseppe
author_facet Gelzo, Monica
Cacciapuoti, Sara
Pinchera, Biagio
De Rosa, Annunziata
Cernera, Gustavo
Scialò, Filippo
Mormile, Mauro
Fabbrocini, Gabriella
Parrella, Roberto
Gentile, Ivan
Castaldo, Giuseppe
author_sort Gelzo, Monica
collection PubMed
description COVID-19 may appear with a widely heterogeneous clinical expression. Thus, predictive markers of the outcome/progression are of paramount relevance. The neutrophil/lymphocyte ratio (NLR) has been suggested as a good predictive marker of disease severity and mortality. Accordingly, we found that NLR significantly increased in parallel with the WHO severity stage in COVID-19 patients during the I(st) wave (March-May 2020; n = 49), due to the significant reduction of lymphocyte and the significant increase of neutrophil in severe COVID-19 patients. While, we did not observe significant differences of NLR between the WHO severity stage among COVID-19 patients of the II(nd) wave (September 2020-April 2021; n = 242). In these patients, the number of lymphocytes and neutrophils did not change significantly between patients of different severity subgroups. This difference likely depends on the steroids therapy that the patients of the II(nd) wave performed before hospitalization while most patients of the I(st) wave were hospitalized soon after diagnosis. This is also confirmed by serum interleukin (IL)-6 and myeloperoxidase (MPO) that gradually increased with the disease stage in patients of the I(st) wave, while such biomarkers (whose production is inhibited by steroids) did not show differences among patients of the II(nd) wave in different stages. Thus, the NLR could be tested at diagnosis in naïve patients before starting therapies.
format Online
Article
Text
id pubmed-8239130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82391302021-06-30 Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy? Gelzo, Monica Cacciapuoti, Sara Pinchera, Biagio De Rosa, Annunziata Cernera, Gustavo Scialò, Filippo Mormile, Mauro Fabbrocini, Gabriella Parrella, Roberto Gentile, Ivan Castaldo, Giuseppe Front Public Health Public Health COVID-19 may appear with a widely heterogeneous clinical expression. Thus, predictive markers of the outcome/progression are of paramount relevance. The neutrophil/lymphocyte ratio (NLR) has been suggested as a good predictive marker of disease severity and mortality. Accordingly, we found that NLR significantly increased in parallel with the WHO severity stage in COVID-19 patients during the I(st) wave (March-May 2020; n = 49), due to the significant reduction of lymphocyte and the significant increase of neutrophil in severe COVID-19 patients. While, we did not observe significant differences of NLR between the WHO severity stage among COVID-19 patients of the II(nd) wave (September 2020-April 2021; n = 242). In these patients, the number of lymphocytes and neutrophils did not change significantly between patients of different severity subgroups. This difference likely depends on the steroids therapy that the patients of the II(nd) wave performed before hospitalization while most patients of the I(st) wave were hospitalized soon after diagnosis. This is also confirmed by serum interleukin (IL)-6 and myeloperoxidase (MPO) that gradually increased with the disease stage in patients of the I(st) wave, while such biomarkers (whose production is inhibited by steroids) did not show differences among patients of the II(nd) wave in different stages. Thus, the NLR could be tested at diagnosis in naïve patients before starting therapies. Frontiers Media S.A. 2021-06-15 /pmc/articles/PMC8239130/ /pubmed/34211953 http://dx.doi.org/10.3389/fpubh.2021.664108 Text en Copyright © 2021 Gelzo, Cacciapuoti, Pinchera, De Rosa, Cernera, Scialò, Mormile, Fabbrocini, Parrella, Gentile and Castaldo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Gelzo, Monica
Cacciapuoti, Sara
Pinchera, Biagio
De Rosa, Annunziata
Cernera, Gustavo
Scialò, Filippo
Mormile, Mauro
Fabbrocini, Gabriella
Parrella, Roberto
Gentile, Ivan
Castaldo, Giuseppe
Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?
title Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?
title_full Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?
title_fullStr Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?
title_full_unstemmed Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?
title_short Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?
title_sort prognostic role of neutrophil to lymphocyte ratio in covid-19 patients: still valid in patients that had started therapy?
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239130/
https://www.ncbi.nlm.nih.gov/pubmed/34211953
http://dx.doi.org/10.3389/fpubh.2021.664108
work_keys_str_mv AT gelzomonica prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT cacciapuotisara prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT pincherabiagio prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT derosaannunziata prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT cerneragustavo prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT scialofilippo prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT mormilemauro prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT fabbrocinigabriella prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT parrellaroberto prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT gentileivan prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy
AT castaldogiuseppe prognosticroleofneutrophiltolymphocyteratioincovid19patientsstillvalidinpatientsthathadstartedtherapy